@inbook{91f49d1d184b439894d9dca7897518f0,
title = "Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases",
abstract = "Aging is the major predictor for developing multiple neurodegenerative diseases, including Alzheimer's disease (AD) other dementias, and Parkinson's disease (PD). Senescent cells, which can drive aging phenotypes, accumulate at etiological sites of many age-related chronic diseases. These cells are resistant to apoptosis and can cause local and systemic dysfunction. Decreasing senescent cell abundance using senolytic drugs, agents that selectively target these cells, alleviates neurodegenerative diseases in preclinical models. In this review, we consider roles of senescent cells in neurodegenerative diseases and potential implications of senolytic agents as an innovative treatment.",
keywords = "Alzheimer's disease, Cellular senescence, Dasatinib, Fisetin, Navitoclax, Parkinson's disease, Quercetin, Senescence-associated secretory phenotype, Senescent cell anti-apoptotic pathways, Senolytics",
author = "{Wissler Gerdes}, {Erin O.} and Yi Zhu and Weigand, {B. Melanie} and Utkarsh Tripathi and Burns, {Terence C.} and Tamar Tchkonia and Kirkland, {James L.}",
note = "Funding Information: The authors are supported by NIH Grants R37AG013925, P01AG062413, and the Translational Geroscience Network (R33AG061456), the Alzheimer's Association Part the Cloud Program, the Alzheimer's Drug Discovery Foundation, Robert and Arlene Kogod, the Connor Group, Robert J. and Theresa W. Ryan, and the Noaber Foundation. J.L.K. T.T. and Y.Z. have a financial interest related to this research. Patents on senolytic drugs are held by Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. No conflicts of interest, financial or otherwise, are declared by E.O.W.G. B.M.W. U.T. or T.C.B. Funding Information: The authors are supported by NIH Grants R37AG013925, P01AG062413, and the Translational Geroscience Network (R33AG061456), the Alzheimer's Association Part the Cloud Program, the Alzheimer's Drug Discovery Foundation, Robert and Arlene Kogod, the Connor Group, Robert J. and Theresa W. Ryan, and the Noaber Foundation. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
doi = "10.1016/bs.irn.2020.03.019",
language = "English (US)",
isbn = "9780128231210",
series = "International Review of Neurobiology",
publisher = "Academic Press Inc",
pages = "203--234",
editor = "Gra{\.z}yna S{\"o}derbom and Russell Esterline and Jan Oscarsson and Mattson, {Mark P.}",
booktitle = "Metabolic and Bioenergetic Drivers of Neurodegenerative Disease",
}